Beacon Therapeutics

MA - CambridgeBiotechnology1 H-1B visas (FY2023)

Focus: Beacon Therapeutics is a Cambridge-based gene therapy biotech founded in 2021, focused on rare inherited retinal diseases and systemic genetic conditions using adeno-associated virus (AAV) vectors. The company is publicly listed with a focused pipeline in early-to-mid stage development.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Beacon Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Beacon Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Clinical and Genetic Characterization of Individuals With Achromatopsia

Achromatopsia

N/A

Clinical Trials (1)

NCT01846052Clinical and Genetic Characterization of Individuals With Achromatopsia

N/A

Help build intelligence for Beacon Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused gene therapy platform targeting high-unmet-need rare diseases (retinal dystrophies, alpha-1 antitrypsin deficiency) with meaningful patient impact
Lead program (rAAV2tYF-GRK1-RPGR) in Phase 2/3 for X-linked retinitis pigmentosa with 4 active trials, offering near-term clinical catalysts
Public company status provides liquidity and potential equity upside while maintaining biotech agility in a strategic specialty

Watch Out For

Zero active job openings and minimal hiring activity suggest limited near-term headcount growth or recent scaling challenges
Early-stage pipeline (5 Phase 1, 9 Phase 2, only 1 Phase 3) carries high clinical risk with no marketed products generating revenue

Generated by Claude from Beacon Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Dorzolamide 2% TID or brinzolamide 1% TID

X-linked Retinoschisis

N/A

Clinical Trials (1)

NCT02331173Clinical Evaluation of Patients With X-linked Retinoschisis

N/A

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

X-Linked Retinitis Pigmentosa

N/A

Clinical Trials (1)

NCT03314207Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

N/A

AGTC-402

Achromatopsia

Phase 1/2

Clinical Trials (1)

NCT02935517Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

Phase 1/2

rAAV2tYF-CB-hRS1

X-linked Retinoschisis

Phase 1/2

Clinical Trials (1)

NCT02416622Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

Phase 1/2

rAAV2tYF-PR1.7-hCNGB3

Achromatopsia

Phase 1/2

Clinical Trials (1)

NCT02599922Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

Phase 1/2

rAAV2tYF-CB-hCNGA3

Achromatopsia

Phase 1/2

rAAV2-CB-hRPE65

Leber Congenital Amaurosis

Phase 1/2

rAAV1-CB-hAAT

Alpha-1 Antitrypsin Deficiency

Phase 2

Clinical Trials (2)

NCT01054339Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

Phase 2

NCT00430768Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency

Phase 1

Adeno-associated virus vector expressing a human RPGR gene

X-Linked Retinitis Pigmentosa (XLRP)

Phase 2

Clinical Trials (1)

NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

Phase 2

AGTC-501

X-Linked Retinitis Pigmentosa

Phase 2

Clinical Trials (2)

NCT06333249A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Phase 2

NCT06275620A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Phase 2

Adeno-associated virus vector expressing human RPGR gene

X-Linked Retinitis Pigmentosa

Phase 2

rAAV2tYF-GRK1-RPGR

X-Linked Retinitis Pigmentosa

Phase 2/3

Clinical Trials (1)

NCT03316560Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Phase 1/2

rAAV2tYF-GRK1-hRPGRco

X-Linked Retinitis Pigmentosa

Phase 2/3

Clinical Trials (1)

NCT04850118A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 13 clinical trials

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub